Please ensure Javascript is enabled for purposes of website accessibility

Here's Why Collegium Pharmaceutical Rose as Much as 23.5% Today

By Maxx Chatsko - Updated Dec 5, 2017 at 12:05PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The company is acquiring a new drug with over $200 million in annual sales, but it won't be cheap.

What happened

Shares of specialty pharmaceutical developer Collegium Pharmaceutical (COLL -4.34%) rose over 23% today after the company announced that it will acquire the pain drug Nucynta from Depomed (ASRT -1.91%). The move will expand its pain management portfolio and its top line -- significantly. 

Investors are also cheering what it could mean for Depomed, which has struggled to justify the $1.05 billion acquisition of Nucynta from Janssen in early 2015. Continually falling sales for the franchise have weighed on the stock this year, so a relatively favorable divestment to Collegium Pharmaceutical could provide more certainty for the company going forward.

As of 11:48 a.m. EST, Collegium Pharmaceutical stock had settled to a 11.9% gain, while Depomed's had settled to a gain of 9.8%

A woman checking her smartphone and pumping her fist as dollar bills fall around her.

Image source: Getty Images.

So what

Aside from the significant increase in revenue that will be achieved, the acquisition is a bit of a head scratcher for Collegium Pharmaceutical for a couple of reasons.

First, the company has begun finding success with its Xtampza brand of abuse-deterrent pain drugs, which are becoming an increasingly important focus for the U.S. Food and Drug Administration as it looks to combat the opioid crisis. That was certainly an important narrative for the company, too, but investors may need to rethink that considering Nucynta has a high risk of dependence and addiction.

Then again, the FDA's intent to speed up the development and commercialization of generic abuse-deterrent drugs poses a risk to brand-name drugs such as Xtampza. From that perspective, it makes sense that Collegium Pharmaceutical would be keen to diversify its business through an acquisition, and the more mature Nucynta is wildly more successful than its own pain product. Through the first nine months of 2017, Xtampza generated $17.7 million in revenue, while Nucynta notched $183.3 million in revenue.  

But the financial details of the deal will significantly erode the increase in sales. For the first four years of the agreement, Collegium Pharmaceutical must pay Depomed a minimum annual license fee of $135 million, plus double-digit royalties on annual sales over $233 million. Given that quarterly sales of Nucynta have been falling throughout 2017, the value of the deal could come into question during that four-year period if the new owner of the brand doesn't find a way to reverse the revenue trend. 

Now what

The high gross margins of Nucynta should allow Collegium Pharmaceutical to benefit financially from the deal -- even after accounting for sizable annual licensing payments -- but perhaps not nearly as much as investors think. The big question now is whether the company's sales force can halt sliding revenue for the drug franchise to increase the long-term value of the acquisition.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Depomed, Inc. Stock Quote
Depomed, Inc.
ASRT
$3.09 (-1.91%) $0.06
Collegium Pharmaceutical, Inc. Stock Quote
Collegium Pharmaceutical, Inc.
COLL
$15.65 (-4.34%) $0.71

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
330%
 
S&P 500 Returns
115%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 05/24/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.